New drug targets Hard-to-Treat cancers with rare gene flaw
NCT ID NCT03284385
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study tests a drug called adavosertib in adults with advanced solid tumors that have a missing or broken SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Siteman Cancer Center at Christian Hospital
St Louis, Missouri, 63136, United States
-
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376, United States
-
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141, United States
-
Siteman Cancer Center-South County
St Louis, Missouri, 63129, United States
-
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, 60451, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UCSF Medical Center-Mission Bay
San Francisco, California, 94158, United States
-
UCSF Medical Center-Mount Zion
San Francisco, California, 94115, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of Chicago Medicine-Orland Park
Orland Park, Illinois, 60462, United States
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
-
University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
-
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, 66205, United States
-
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, 37204, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, 48334, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return